Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.76 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.76 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.62 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.62 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.62 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.62 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.62 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.62 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | FABP3 | P05413 | 1/20 | 0.58 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | CDC25A | P30304 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30652127 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL29482586 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| Lysophosphatidylcholine SCHEMBL29651472 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL9015289 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| Lysophosphatidylcholine SCHEMBL19787878 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL11131776 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL31577414 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL31122371 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL9560238 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 | |
| SCHEMBL19065066 | 1.00 | SMN1; SMN2 (0.76) | SMN1; SMN2NR5A2NR5A1MAPTLPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| CN-114728078-A | Extracellular vesicles linked to molecules and uses thereof | 科迪亚克生物科学公司 | 2022-07-08 | — | — | CN | claimed |
| US-5352673-A | Administering to inactivate or inhibit phospholipase A | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE A CORP. OF CALIFORNIA | 1994-10-04 | — | — | US | claimed |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-119948163-A | CEBP/beta targeted extracellular vesicle-ASO constructs | 隆萨销售股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4470619-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Lonza Sales AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| CN-113747925-B | Extracellular vesicle conjugates and uses thereof | 隆萨销售股份公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20240318187-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | MODERNATX INC (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240254481-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2024-08-01 | — | — | US | disclosed |
| EP-4013877-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013872-A1 | EXTRACELLULAR VESICLES WITH ANTISENSE OLIGONUCLEOTIDES TARGETING KRAS | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-4013878-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Codiak BioSciences, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114641570-A | Extracellular vesicles with KRAS-targeted antisense oligonucleotides | 科迪亚克生物科学公司 | 2022-06-17 | — | — | CN | disclosed |
| US-5567597-A | DIAGNOSING THE DISEASE BY DETECTING, MEASURING THE LIPASE, PHOSPHOLIPASE, ESTERASE, PROTEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1996-10-22 | — | — | US | disclosed |
| US-5427919-A | Therapy, analysis substrates | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-06-27 | — | — | US | disclosed |
| US-5352673-A | Administering to inactivate or inhibit phospholipase A | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE A CORP. OF CALIFORNIA | 1994-10-04 | — | — | US | disclosed |
| US-5308766-A | Hydrolytic enzyme inhibitors/inactivators and methods for using same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-05-03 | — | — | US | disclosed |
| WO-1992022289-A1 | NOVEL PHOSPHOLIPASE A2 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT5B | SMN1; SMN2 542/4885NR5A2 2931/4885NR5A1 3625/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | SMN1; SMN2 1119/4885NR5A2 1807/4885NR5A1 1445/4885 |
| US-20240318187-A1 | POLYRIBONUCLEOTIDES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF | UPF1, NUDT21, RNMT | SMN1; SMN2 556/4885NR5A2 4692/4885NR5A1 4696/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.